RTP Mobile Logo
Select Publications

Arance AM et al. Combination treatment with cobimetinib (C) and atezolizumab (A) vs pembrolizumab (P) in previously untreated patients (pts) with BRAFV600 wild type (wt) advanced melanoma: Primary analysis from the phase 3 IMspire170 trial. Proc ESMO 2019;Abstract LBA69.

Ascierto PA et al. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nat Med 2019;25(6):941-6. Abstract

Ascierto PA, Eggermont AMM. Neoadjuvant therapy in melanoma: The next step? Lancet Oncol 2018;19(2):151-3. Abstract

Carlino MS et al. Pembrolizumab versus placebo as adjuvant therapy in resected high-risk stage II melanoma: Phase 3 KEYNOTE-716 study. ASCO 2019;Abstract TPS9596.

Da Silva IEDP et al. Comprehensive molecular profiling of metastatic melanoma to predict response to monotherapy and combination immunotherapy. ASCO 2019;Abstract 9511.

Drago JZ et al. Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: A real-life multicenter study. Melanoma Res 2019;29(1):65-9. Abstract

Dummer R et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2018;19(5):603-15. Abstract

Dummer R et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): A multicentre, open-label, randomised, phase 3 trial. Lancet 2018;19(10):1315-27. Abstract

Eggermont AMM et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med 2018;378:1789-801. Abstract

Eggermont AMM et al. Combination immunotherapy development in melanoma. Am Soc Clin Oncol Educ Book 2018;38:197-207. Abstract

Gonzalez M et al. A phase II, open label, randomized controlled trial of nivolumab plus ipilimumab with stereotactic radiotherapy versus ipilimumab plus nivolumab alone in patients with melanoma brain metastases (ABC-X Trial). ASCO 2019;Abstract TPS9600.

Hauschild A et al. Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600-mutant stage III melanoma. J Clin Oncol 2018;[Epub ahead of print]. Abstract

Hodi FS et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol 2018;19(11):1480-92. Abstract

Larkin JMG et al. 5-year survival outcomes of the CheckMate 067 phase 3 trial of nivolumab plus ipilimumab (NIVO + IPI) combination therapy in advanced melanoma. ESMO 2019;Abstract LBA68_PR.

Long GV et al. Long-term outcomes from the randomized ph 2 study of nivolumab (nivo) or nivo + ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets): Anti-PD1 brain collaboration (ABC). Proc ESMO 2019;Abstract 1311O.

Luke JJ et al. Targeted agents or immuno-oncology therapies as first-line therapy for BRAF-mutated metastatic melanoma: A real-world study. Future Oncol 2019;15(25):2933-42. Abstract

Nathan PD et al. Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600–mutant unresectable or metastatic melanoma. ASCO 2019;Abstract 9507.

Osgood C et al. FDA analysis of depth of response (DpR) and survival across 10 randomized controlled trials in patients with previously untreated unresectable or metastatic melanoma (UMM) by therapy type. ASCO 2019;Abstract 9508.

Owen CN et al. A multicenter analysis of melanoma recurrence following adjuvant anti-PD1 therapy. ASCO 2019;Abstract 9502.

Pavlick AC et al. Frontline therapy for BRAF-mutated metastatic melanoma: How do you choose, and is there one correct answer? Am Soc Clin Oncol Educ Book 2019;39:564-71. Abstract

Postow MA. Does adjuvant therapy for high-risk melanoma with either immunotherapy or targeted therapy affect therapeutic choices at relapse? Clin Adv Hematol Oncol 2018;16(5):353-5. Abstract

Ribas A et al. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma. Nat Med 2019;25(6):936-40. Abstract

Robert C et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med 2019;381(7):626-36. Abstract

Saab KR et al. Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy. Cancer 2019;125(6):884-91. Abstract

Schadendorf D et al. Adjuvant immunotherapy with nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma patients with no evidence of disease (NED): A randomized, double-blind phase 2 trial (IMMUNED). ESMO 2019;Abstract LBA67.

Shoushtari AN et al. Measuring toxic effects and time to treatment failure for nivolumab plus ipilimumab in melanoma. JAMA Oncol 2018;4(1):98-101. Abstract

Sullivan RJ et al. Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. Nat Med 2019;25(6):929-35. Abstract

Tawbi HA et al. Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204). ASCO 2019;Abstract 9501.

Tawbi HA et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med 2018;379(8):722-30. Abstract

Valpione S et al. Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study. Eur J Cancer 2018;91:116-24. Abstract

Weber JS et al. Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase 3 CheckMate 238 trial. ESMO 2019;Abstract 1310O.